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Session: Disease & Treatment 95for TRO-BMD, IGSF11). We also replicated two loci 3p21 (rs148725943, discovery
pZ6.61x10-7, replication pZ5.22x10-4 for TRO-BMD, CTNNB1) and 8q24
(rs7839059, discovery pZ2.28x10-7, replication pZ1.55x10-3 for TRO-BMD,
TNFRSF11B) that were reported previously.
Conclusion: Our findings provide useful insights that enhance our understanding of
bone development, osteoporosis, and fracture pathogenesis.
http://dx.doi.org/10.1016/j.jot.2016.06.083253
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Introduction: Themajority of long bone fractures heal successfully without compli-
cations; however fractures resulting from high impact trauma can result in delayed
healing or non-union. Early intervention could decrease patient morbidity and
reducehealth care systemcosts. Photodynamic therapy (PDT) is aminimally invasive
local treatment involving administration of a photosensitizer, which is activated by
laser light leading to the production of singlet oxygen, which can induce apoptosis
and/or necrosis of targeted cells and tissue and also influence immune responses.
PDT treatment of metastatically involved vertebrae resulted in improved vertebral
bone strength, stiffness and architecture,motivating studying PDTas an approach to
augment bone healing. The aim of this studywas to evaluate the ability of PDT treat-
ment to enhance healing in fractures exhibiting critically size defects.
Materials and Methods: Femoral fractures with critically sized defects (6 mm)
were generated in 30 adult female Sprague-Dawley rats (7 or 15 week survival).
Under general anaesthesia an 8-hole PEEK plate was attached laterally to the fe-
mur. Using a Gigly saw, a bone piece was removed followed by closure of muscu-
lature and skin. Rats were randomly allocated to three groups: control, PDT
applied either 1 day, or 7 days post fracture. A photosensitizer (Visudyne, Novartis,
Canada) was injected (1mg/kg) followed 15 minutes later by light delivery (75J;
690 nm) using a 1 cm diffuser fibre placed parallel to the fracture. The rats
were euthanized 7 or 15 weeks after induction of the fracture. mCT images of
the femur at an isotropic 13.3 mm/voxel resolution (Inveon MicroCT, Siemens, Ger-
many) were acquired and analysed (AmiraDev 5.2, FEI Visualization Science Group,
USA). Thereafter, the bone was decalcified and processed for histology. Statistical
analysis was performed using a 1-way ANOVA.
Results: All rats recovered well; however five animals were euthanized early due
to plate displacement. The total bone volume (TV) evaluated from mCT images
within the fracture gap did not show significant differences. In contrast, BMD
(gHA/cm2) trended toward higher values in the PDT treated groups compared to
controls. The fracture gap measured on mCT images of the 7 week group demon-
strated a trend toward smaller gaps in the PDT treated groups (pZ 0.0535). A sta-
tistically significant (pZ 0.0085) smaller gap is present in the PDT treated groups
after 15 weeks. Histology of the control group showed more cartilage and woven
bone formation in contrast to the PDT treated groups which exhibited more struc-
tured and mature bone.
Discussion: PDT treatment of rat femur fractures led to lower overall formation of
bone, but the bone had higher density with a decrease in the size of the fracture
gap. The increase in bone density in the PDT treated groups may suggest formation
of better quality bone (vs. quantity of bone). Histologically, with more cartilage
and woven bone present in the control group in contrast to more mature bone
and in the PDT group, the fracture healing seems to follow a different pattern,
which requires further investigation.
Funding/support: Congressionally directed Medical Research programs (CDMRP),
grant # OR090260.
http://dx.doi.org/10.1016/j.jot.2016.06.084258
PATHOPHYSIOLOGY OF CHEMOTHERAPY-INDUCED DAMAGE OF BONE MARROW
MICRO-VASCULATURE AND POTENTIAL PROTECTIVE EFFECTS OF FLAVONOIDS
IN RATS
Mohammadhossein Hassanshahi
University of South Australia, Australia
Introduction: It has been widely shown that bone formation and remodelling
would not occur unless there is already a properly established micro-vasculature.
However, blood vessels can be damaged by extrinsic causes such as chemothera-
peutic agents. Methotrexate (MTX) is an anti-metabolite chemo-agent widely
used in treatment of many diseases including childhood leukaemia and inflamma-
tory disorders. While previous studies showed that MTX can cause long-term skel-
etal side effects, whether and how it damages bone marrow micro-vasculatureremains unclear. Using a rat model and endothelial cell-culture models, we
addressed these questions. In addition, since we recently showed that the osteo-
genic, anti-oxidant, and anti-inflammatory flavonoid genistein can protect bone in
MTX-treated rats, here we also investigated effects of genistein in the recovery of
damaged blood vessels in rats treated with MTX. Furthermore, we also examined
potential treatment effects of genistein and a related flavonoid, icariin, on
viability and tube-formation ability of endothelial cells treated with MTX in vitro.
Methods: Animal studies: To study the effect of MTX on blood vessels, groups of
male (6-week-old) SpragueeDawley rats were subcutaneously injected with MTX
(0.75mg/kg) once daily for 5 days and were sacrificed on day 1, 3, 6, 9, 11, and
14. To study the protective effects of genistein, in some MTX-treated rats, genis-
tein was administrated by oral gavage (2 mg/100 g BW) for the whole period start-
ing from day 0 until one day before kill (day 9). Treatment effects on number and
sizes of bone marrow micro blood vessels were examined histologically in tibiae.
MTT viability assay: Concentration-/time- dependent treatment effects of MTX
(10nM-10mM) were examined on viability of cultured rat sinusoid endothelial cells
(SECs) and effects of 24 hour treatment with MTX plus icariin/genistein (10nM-
10mM) were also studied. Apoptosis detection by flow cytometry: SECs were
treated with MTX (1mM/mL) for 24 and 48 hours and apoptosis was detected based
on their cell surface Annexin-V expression. Tube formation assay: SECs were
treated with/without MTX (1mM), icariin or genistein (100nM-10mM) and effects
on angiogenesis were examined based on formation of tubes by SECs on Matrigel.
Results: Histological image analyses of H&E-stained tibial sections showed significant
blood vessel damage in the bone marrow of rats on days 6 and 9 and significant but
partial recovery ondays 11 and 14 following the first MTX dose.Histologyanalyses sug-
gested that genistein potentially attenuates MTX-induced blood vessel damage in the
bone marrow. Examining any cytotoxic effect of MTX on endothelial cells, MTTassays
showed that the viability of SECs was not affected after 24 hours of treatment with
MTX (10nM-10mM). However, following 48 hour treatment, viability of SECs was
reduced in a concentration-dependant manner. Flow cytometry analysis revealed
that SECs underwent apoptosis following 48 hours (but not 24 hours) treatment with
MTX (1mM). MTT assays also showed that neither genistein nor icariin treatment
affected viability of SECs viability. Tube formation assays showed a reduced tube for-
mation potential of SECs treated with MTX (1mM). Interestingly, icariin or genistein
(10mM)-treated SECs showed enhanced tube formation and icariin or genistein treat-
ment can prevent MTX-induced decrease in tube formation.
Discussion and Conclusion: Our in vivo and in vitro studies suggest that MTX
causes blood vessel damage in the bone marrow, potentially by inducing apoptosis
in endothelial cells and also interfering in the process of angiogenesis. Our in vitro
tube formation assays showed that icariin and genistein might not only promote
angiogenesis but possess some protective effect against MTX damage. Consis-
tently, our in vivo studies also showed some positive effects of genistein treatment
in reducing MTX-induced blood vessel damage in the bone marrow of rats.
http://dx.doi.org/10.1016/j.jot.2016.06.085259
INCREASED EZH2 COMBINED WITH DECREASED OSTEOBLASTOGENESIS IN
LOCAL IRRADIATION INDUCED RAT BONE LOSS
Changjun Guo, Changwei Li, Lianfu Deng
Shanghai Institute of Traumatology and Orthopaedics, China
Radiation therapy is a common treatment for cancer patients. The adverseeffects are
the insufficiency fractures and bone loss. Epigenetic regulation plays an important
role in the BMSCs differentiation. We reported here, the changes of local bone after a
single-dose 137CS irradiation exposure in rats. The bone mineral density (BMD) of the
femur and the trabecular bone volume in the tibia were significantly decreased at 12
weeks after irradiation. The micro-CT results showed that the tBMD, Tb.h, and Tb.N
were also significantly reduced after 12 weeks of irradiation exposure. The ALP-pos-
itive OB.S/BS was decreased by 42.3% after 2 weeks irradiation, and decreased by
50.8% at the 12 weeks. In contrast to the decreased expression of Runx2 and BMP2,
we found EZH2 expression was significantly increased after 2 weeks of single-dose
137CS irradiation in BMSCs. In conclusion, our results demonstrated that the single-
dose 137CS irradiation induces the loss of BMD and bone micro-architecture deteriora-
tion in rat skeleton,aswell as the increasedexpression of EZH2anddecrease of osteo-
blastogenesis after irradiation. The underlying mechanisms may be required to
further investigate the relationship.
http://dx.doi.org/10.1016/j.jot.2016.06.086261
MYRICITRIN INHIBITS OSTEOCLASTOGENESIS
Weiguang Lu, Liu Yang, Zhuojing Luo
The Fourth Military Medical University, Xijing Hospital, China
Myricitrin is a botanical flavonol glycoside, extracted from leaves of Myrica ceri-
fera and other plants. Abundant evidence supports myricitrin has anti-oxidative,
anti-inflammatory, and neuroprotective effects. Osteoclastic bone resorption is
96 Session: Disease & Treatmentvital to maintain the balance of bone homeostasis. Our early article elucidated
myricitrin could protect from osteoporotic bone mass reduction via reducing reac-
tive oxygen species (ROS) in osteoblastic bone formation; however, the influence
of osteoclastogenesis by myricitrin is still unclear. Here, we exhibited that myrici-
trin could decrease the TRAP positive cell number significantly in a dose-depen-
dent manner during osteoclast maturation, but it had no effect to pre-osteoclast
proliferation. Consistently, osteoclast maturation markers, and the bone resorp-
tive pits number and area were decreased. Taken together, myricitrin could inhibit
osteoclastogenesis.
http://dx.doi.org/10.1016/j.jot.2016.06.087297
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Background: Telomere length plays a vital role in genomic stability and shortened
telomeres may cause genomic instability and carcinogenesis. Mitochondria exert a
potential role in energy metabolism, free radical production, apoptosis, and may
be involved in cancer progression. Both telomere length and alteration of mito-
chondrial DNA (mtDNA) copy number have been proposed as biomarkers for several
cancers. Nevertheless, few studies have examined the association of telomere
length and mtDNA copy number in musculoskeletal tumours. This study aimed to
examine telomere length and mtDNA copy number in peripheral blood leukocytes,
neoplastic tissues, and non-neoplastic adjacent tissues of patients with musculo-
skeletal tumours. The second objective of this study was to investigate the rela-
tionship of telomere length and mtDNA copy number in musculoskeletal tumours.
Subjects and Methods: Peripheral blood leukocytes (nZ41), neoplastic tissues
(nZ46), and non-neoplastic adjacent tissues (nZ32) were obtained from patients
with musculoskeletal tumours. Relative telomere length and relative mtDNA copy
number were evaluated by quantitative real-time polymerase chain reaction.
Results: Relative telomere length in neoplastic tissues was significantly shorter than
that in non- neoplastic adjacent tissues (p Z 0.001). Shorter relative telomere
length in neoplastic tissues compared to non-neoplastic tissues was observed in
female and male (pZ 0.018 and pZ 0.019, respectively). In addition, the relative
telomere length in malignant tissues was significantly decreased as compared with
that in adjacent non-neoplastic tissues (p Z 0.016). While the relative telomere
length in malignant tissues seemed to be lower than that in benign tissues, there
was no significant difference. The relative telomere length in peripheral blood
leukocytes was not correlated with that in neoplastic tissues. In contrast, relative
mtDNA copy number in neoplastic tissues was not different when compared to
that in non-neoplastic adjacent tissues. The relative mtDNA copy number in periph-
eral blood leukocytes was not associated with that in neoplastic tissues. Interest-
ingly, relative mtDNA copy number in neoplastic tissues was significantly higher
than that in peripheral blood leukocytes (p < 0.001). Further analysis showed that
there was a negative association between relative telomere length and mtDNA
copy number in patients with musculoskeletal tumours (rZ -0.306; pZ 0.104).
Discussion and Conclusion: Relative telomere length in neoplastic tissues was
significantly shorter than that in non-neoplastic adjacent tissues, suggesting that
neoplastic tissues (especially malignant tissues) may undergo several cell divisions
which could lead to progressively shorter telomeres. This finding demonstrated
that relative mtDNA copy number in tissues was significantly higher than that in pe-
ripheral blood leukocytes. The explanation of this finding could be due to speci-
ficity of mtDNA copy number in different types of tissues. The relative telomere
length is inversely associated with the relative mtDNA copy number, indicating
that telomere length attrition and mtDNA alteration are necessary events in
musculoskeletal tumour progression.
http://dx.doi.org/10.1016/j.jot.2016.06.088340
DOWN-REGULATION OF m-OPIOID RECEPTOR MEDIATED EPIGENETICALLY BY
NEURON-RESTRICTIVE SILENCER FACTOR IS INVOLVED IN THE REDUCED
MORPHINE ANALGESIA IN A BONE CANCER PAIN ANIMAL MODEL
Chao Zhu, Tan Ding, Liu Yang, Zhe Wang, Zhuo-Jing Luo
Xijing Hospital, The Fourth Military Medical University, China
Background: Primary and metastatic cancers that affect bone are frequently asso-
ciated with severe and intractable pain. Bone cancer pain has been reported with
unique mechanisms and is resistant to morphine treatment. Previous studies have
indicated that change of m-opioid receptor (MOR) expression may be involved in
the pathogenesis of bone cancer pain. In addition, neuron-restrictive silencerfactor (NRSF) has been recently reported to modulate transcription of the MOR
gene. The present study elucidates the regulatory mechanisms of MOR and its po-
tential to effect bone cancer pain.
Methods: Using a sarcoma inoculated murine model, pain behaviours that repre-
sent continuous or breakthrough pain were evaluated. Immunofluorescent staining
was used to check the expression of NRSF in the dorsal root ganglion (DRG).
Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot anal-
ysis were used to quantify expression of NRSF at the transcriptional and transla-
tional levels, respectively. Additionally, chromatin immunoprecipitation assays
were used to detect NRSF binding to the promoter of MOR. Furthermore, NRSF
was genetically knocked out by antisense oligodeoxynucleotide (AS-ODN), and
the expression of MOR and the effect of morphine were subsequently analysed.
Results: Our results indicated that in a sarcoma murine model, expression of NRSF
is upregulated in the DRG neurons and the expression of NRSF mRNA is significantly
negatively correlated with expression of MOR mRNA. Additionally, chromatin
immunoprecipitation analysis revealed that NRSF binding to the neuron-restrictive
silencer element within the promoter area of the MOR gene is significantly pro-
moted with a hypo-acetylation state of histone H3. Furthermore, genetically
knocking down of NRSF with AS-ODN rescued the expression of MOR, with potenti-
ation of system morphine analgesia.
Discussion and Conclusion: The present results suggest that in sarcoma induced
bone cancer pain, NRSF induced downregulation of MOR is involved in the reduction
of morphine analgesia. Epigenetically, up-regulation of MOR could substantially
improve the effect of system delivery of morphine. The results indicate that NRSF
plays an important role in the modulation of MOR transcription and may represent
a novel analgesic target for bone cancer pain. What should be noted is that the
expression of opioid receptors are not only regulated at the transcriptional level,
but are also controlled by extensive post-transcriptional processing. Further studies
are needed at both the preclinical and clinical levels to develop pharmacological
therapy and to effectively block/relieve bone cancer pain with the goal of
increasing the functional status and quality of life of humans with bone cancer pain.
http://dx.doi.org/10.1016/j.jot.2016.06.089367
miR-138-5p TARGETS MACF1 TO INHIBIT BONE FORMATION
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Introduction: MicroRNAs (miRNAs) play important roles in the regulation of target
gene expression to coordinate a broad spectrum of biological processes. There is
increasing evidence that multiple miRNAs serve as important regulators of osteoblast
differentiation and bone formation. Significantly, recent studies have discovered that
miR-214, miR-103a, and miR-103, were sensitive to mechanical stimulation to regu-
late osteoblast differentiation or proliferation. However, functional roles of miRNAs
in mechano-transduction in bone formation and further mechanisms in vivo and in vi-
tro have not been well-characterised and, therefore, particularly remain to be eluci-
dated. This study aimed to identify specific miRNAs and their regulatory roles in the
process of bone loss induced by mechanical unloading condition.
SubjectsandMethods:Bonespecimensfrom70osteoporotic individualswithbedridden
states were collected. Twenty-one-month mice and HLU mice were used as the osteo-
porosis model. The RPM machine as an unloading model was used to culture cells.
Results: We assessed the expression of miRNAs involved in bone formation in bone
specimens from 70 osteoporotic individuals with bedridden states in clinical set-
tings. The expression of miR-138-5p altered with bedridden time and was nega-
tively correlated with the expression of the bone formation marker genes ALP in
bedridden women and men. Moreover, consistent results were found in bone tissue
and ALP positive cells in hind limb unloading (HLU) and 20-month aging mice. In
addition, we found that high miR-138-5p expression increased gradually and ALP
activity decreased in osteoblasts after RPM treatment for 12, 24, 48 hours. Target
prediction analysis tools and luciferase activity were used to confirm microtubule
actin crosslinking factor 1 (MACF1) as a direct target of miR-138-5p, and miR-138-
5p inhibited MACF1 expression and osteoblast differentiation in vitro. We treated
mouse preosteoblast MC3T3-E1 cells with antagomir-138-5p and cultured cells un-
der RPM condition. The results indicated that miR-138-5p functions as a mechani-
cal unloading sensitive miRNA and plays a negative role in RPM-induced osteoblast
differentiation reduction. Predominantly, we found an inhibitory role of miR-138-
5p in regulating the bone formation in HLU mice and in vivo pre-treatment with
antagomir-138-5p partly recovered the bone loss caused by hind limb unloading.
Discussion and Conclusion: Taken together, these results suggest that in vivo in-
hibition of miR-138-5p by antimiR-138-5p could represent a potential therapeutic
strategy for ameliorating bone loss.
Funding/support: This work was supported by the National Natural Science Foun-
dation of China (31400725, 31570940).
